semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Coagulation Disorder COVID 19 critically ill patients  any critical illness not related to COVID 19
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Respiratory Distress Syndrome Severe Acute Respiratory Syndrome Due to Coronavirus (SARS-CoV2) Mechanical Ventilation Patients under mechanical ventilation with ARDS (Berlin definition) caused by SARS-COV2 infection ARDS diagnosis in less than 24 hours Respiratory System Compliance of 0.6 mL/cmH2O/Kg of PBW  Age < 18 years Active bronchopleural fistula History of chronic and disabling respirator disease, requiring home oxygen treatment Chronic pulmonary arterial hypertension (pulmonary artery systolic pressure > 40 mmHg) Huge intrathoracic tumoral mass Electrical impedance tomography monitoring contraindications (as thoracic wounds or burns, electronic implantable devices) Hemodynamic instability (systolic pressure < 80 mmHg or mean arterial pressure < 60 mmHg, despite vasopressor drugs; and/or heart rate < 55bpm) this patient may be included after recovered from hemodynamic instability Not drained pneumothorax or subcutaneous emphysema or bronchopleural fistula Patients at risk of intracranial hypertension development or post Cardiopulmonary resuscitation (first 72 hours)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Covid19 Pneumonia Men and women 18 years of age and older COVID-19 documentary confirmed by PCR lab test severe pneumonia caused by COVID-19 according to the below fever or suspicion of respiratory infection the number of respiratory movements 30 per 1 min and above severe respiratory failure or SpO2 <90% with spontaneous breathing indoors the presence of foci of inflammation in the lungs according to the results of computed tomography, which is documented or if any of the conditions listed below have developed on the background of previously diagnosed coronavirus pneumonia severe respiratory failure required mechanical ventilation (ALV) acute respiratory distress syndrome according to WHO diagnostic (development within one week after the manifestation of disease clinical symptoms or emergence of new ones or deterioration of respiratory syndromes. Chest visualization (lung X-ray, CT or ultrasound); bilateral opacities not fully explaining the gravity of condition or lung collapse or nodules)  known intolerance to plasma or immunoglobulin drugs drug allergy or hypersensitization to immunoglobulin drugs any known counter-indication to immunoglobulin drugs according to the instruction for medical application of the tested drug pneumonia not associated with COVID-19 infection pregnancy, lactation period any clinically significant impairment of liver function (elevation of serum transaminase levels more than 3 times the upper limit of normal) serum creatinine levels more than 2 times the upper limit of normal for a given age and gender established diagnosis of primary immunodeficiency verified HIV-infection immune diseases (blood immune diseases, rheumatic diseases, nephritis, etc.)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  End Stage Renal Disease on Dialysis On haemodialysis for at least 3 months Haemodialysis 3 times per week Age 18 years or older  Central venous catheter Planned kidney transplant during the duration of study
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 30.0-75.0,  High Blood Pressure Participants with clinic blood pressure more than or equal to 130/80 mm Hg who are not taking medication Participants with controlled blood pressure defined as < 130/80 using anti-hypertensive medication for a minimum of six weeks Participants live in Banshgram Union only  Aged > 75 years of age Pregnant women People who have advanced CVDs or are any serious condition that restricts their participation in the study Participants will be withdrawn from the study if they are unwilling to continue their participation and withdraw their consent, or any women participants who become pregnant during the study
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  COVID-19 Respiratory Failure ARDS Patient/legally authorized representative has completed the Informed Consent Form Age ≥18 years Ability to comply with the study protocol, in the investigator's judgment Respiratory failure secondary to COVID-19 requiring mechanical ventilation for no greater than 24 hours, or high-flow nasal cannula (HFNC),non-rebreather (NRB) mask or non-invasive positive pressure ventilation (NIPPV) for no greater than 48 hours Confirmed infection with SARS-CoV-2 virus (PCR positive within 14 days) Elevated D-dimer (>6 times upper limit of normal within past 72 hours) For patient who are intubated >12 hours prior to randomization or with any evidence of neurologic deficit a head CT within 12 hours demonstrating no evidence of acute or subacute infarct or hemorrhage  Current participation in another investigational drug study within the prior 7 days Known hypersensitivity or allergy to any ingredients of tenecteplase Active internal bleeding Known bleeding diathesis Use of one of the new oral anticoagulants within the last 48 hours (dabigatran, rivaroxaban, apixaban, edoxaban) Treatment with a thrombolytic within the last 3 months prior to randomization (exception for the use of Cathflo alteplase for occlusions of central venous catheters) Baseline platelet count <80,000/L (results must be available prior to treatment) Baseline blood glucose >400 mg/dL (22.20 mmol/L) Baseline blood glucose <50 mg/dL needs to be normalized prior to randomization Intracranial or intraspinal surgery or trauma within 2 months
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  High Flow Nasal Cannula Sepsis Syndrome Age older than 20 years Pneumonia definitions Diagnosis on admission was sepsis due to pneumonia or septic shock (Sepsis-3)  Patients with human immunodeficiency virus (HIV) Pregnant women There are contraindications to the inability to use HFNC The patient who refuses to insert an endotracheal tube The patient who has tracheostomy The patient who use norepinaphrine（Levophed）≧0.75 mcg/kg/min。 The patient who meet the definition of endotracheal tube insertion The patient who meet the definition of noninvasive ventilation, NIV The patient who has risk factors prone to sepsis（Kidney infection and UTI, abdominal, skin and soft tissue, fever of unknown origin, surgical wound, IV/central/dialysis catheter, meningitis）。
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Covid19 Thrombotic Microangiopathies Acute Kidney Injury Males or Females 18 years of age or above and weighing 40kg or above at the time of providing informed consent. 2. A clinical diagnosis of thrombotic microangiopathy will then be applied to the following i) D-dimer > 100% the upper limit of the reference range and ii) serum creatinine >25% of the normal range or iii) >25% increase from patient's baseline serum creatinine. 3. Diagnosis of SARS-CoV-2 infection within 90 days prior to enrollment  Participant is not expected to survive more than 24 hours. 2. Participant has an unresolved Neisseria Meningitides infection. 3. Hypersensitivity to murine proteins or to one of the excipients of ravulizumab
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sepsis Septic Shock All patients who develop sepsis or septic shock within < 24 h in accordance with the new sepsis definition (Sepsis-3) in the above-mentioned participating centers and consent to participation in the study will be included. General Written consent by the study participant or a legally appointed representative Age >18 years Sepsis Life-threatening organ dysfunction due to a dysregulated immune response on the basis of a suspected or proven infection Detection of organ dysfunction indicated by SOFA score of ≥ 2 points Alternative: Change of the quick (q) SOFA score of 2 points as an indication of a sepsis Or septic shock Persistent hypotension despite adequate volume substitution, which necessitates the use of vasopressors, to maintain an arterial medium pressure of > 65 mmHg Serum lactate > 2 mmol/l (18 mg/dl)  Age < 18 years Refusal to participate in the study Probable discharge of the patient from the intensive care unit within the first 72 h of initial study Palliative therapy approach Death of the patient is already foreseeable or inevitable at trial Patients who have already been included in the study but require re-admission to the intensive care unit cannot be included a second
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Covid19 SARS-CoV-2 PNEUMONIA COVID-19 Ability to understand the study objectives and risks and provide signed and dated informed consent COVID-19 infection (by PCR or antibody test or high probability of COVID-19 by CT) Pneumonia requiring hospitalization, and oxygen saturation of <93%, need for noninvasive ventilation. The confirmed volume of lung damage by CT ability to proceed with inhalation by self  Severe respiratory failure at the time of screening due to COVID-19 pneumonia Known to undergo medical resuscitation for 14 days before randomization Any serious medical condition or deviation of the clinical laboratory parameter that, in the opinion of the researcher, prevents safe participation and completion of the study by the participant Confirmed uncontrolled active bacterial, fungal, viral or other infection (other than SARS-CoV-2) According to the researcher, the progression to death is inevitable and will occur within the next 24 hours, regardless of the therapy The life expectancy of fewer than 28 days, taking into account a medical condition already existing that cannot be corrected, e.g. participants with the following conditions or suspicions: polyorganic insufficiency, poorly controlled neoplasms, terminal stage heart disease, cardiopulmonary cardiac arrest that required cardiopulmonary resuscitation, or electrical activity not accompanied by a pulse, or asystole within the last 30 days, terminal stage liver disease, terminal stage liver disease, or liver disease Pregnancy or breastfeeding Liver function failure (Class C for Child-Pugh), detected within 24 hours at screening (local laboratory) Absolute neutrophil count (ANC) <500 cells/µL at screening (local laboratory) Platelet count <50000 cells/µL at screening (based on laboratory data) Creatinine level ≥ 1.5 from the upper limit
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Pneumonia All patients ≥ 12 years of age with pneumonia: defined by the J-18.X pneumonia code or acute respiratory failure or sepsis with secondary pneumonia codes Survey All physicians and advanced practice clinicians who are employed and actively seeing patients in the 4 Utah Valley Instacares  Patients without radiographic confirmation of pneumonia Subsequent episodes of pneumonia within 12 months (so as not to over-represent patients with recurrent pneumonia caused by recurrent aspiration or structural lung disease). Survey No providers will be excluded from the survey invitation
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Anemia Chronic Liver Disease Age 18-75 years 2. Either gender 3. Patients with chronic liver disease with anemia (Hemoglobin in Non-pregnant women (18 years of age and above) <12g/dl and in men <13g/dl  Those who do not consent to participate in the study 2. Renal dysfunction (S. Creatinine ≥ 2mg/dL) 3. Pregnancy/Lactation 4. Post liver transplant patients 5. HIV infection 6. Patients who are on psychoactive drugs, like sedatives or antidepressants 7. Patients with uncontrolled sepsis 8. Patients who are too sick to carry out the protocol 9. Patients with ongoing active bleeding 10. Patients with known primary hematological disorders
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 40.0-50.0,  Valvular Heart Disease age between 40 and 50 years, female gender 2. hemodynamic stability 3. BMI from 25 to 29.9 kg/m2 4. they will have acute sternal instability  previous thoracic surgery 2. elective and urgent coronary artery bypass surgery 3. respiratory insufficiency after surgery manifesting hypoxemia with partial pressure of oxygen in arterial blood <60 mmHg 4. renal insufficiency with serum creatinine ≥1.8 mg/dl after surgery 5. low cardiac output syndrome with ST segment elevation in multiple electrocardiogram leads, cardiac arrhythmias, or hypotension, according to the American College of Cardiology Foundation and American Heart Association 6. other medical conditions such as diabetes, uncontrolled hypertension and obesity 7. Past medical history that conditions that may have influenced the provision of physiotherapy interventions such as (severe asthma, chronic airflow limitation, bronchiectasis, ankylosing spondylitis or lumbar disc prolapse
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Mesenteric Ischemia Older than 18 years of age Required urgent laparotomy with a postoperative diagnosis of acute mesenteric ischemia Attended the private academic hospital, between 2012 and 2018 Had a registered serum lactate dehydrogenase at admission  Secondary causes of AMI Chronic intestinal ischemic Patient records with no description of the serum lactate dehydrogenase or extension of intestinal necrosis